Your browser is no longer supported. Please, upgrade your browser.
BMRA Biomerica, Inc. monthly Stock Chart
Biomerica, Inc.
Index- P/E- EPS (ttm)-0.27 Insider Own11.10% Shs Outstand9.82M Perf Week6.63%
Market Cap95.50M Forward P/E- EPS next Y-0.10 Insider Trans-0.81% Shs Float9.18M Perf Month41.76%
Income-2.60M PEG- EPS next Q-0.06 Inst Own9.50% Short Float2.86% Perf Quarter21.88%
Sales5.10M P/S18.73 EPS this Y-51.90% Inst Trans36.47% Short Ratio0.30 Perf Half Y191.12%
Book/sh0.47 P/B18.49 EPS next Y58.30% ROA-38.80% Target Price11.00 Perf Year229.18%
Cash/sh0.22 P/C39.79 EPS next 5Y- ROE-67.60% 52W Range2.05 - 23.39 Perf YTD187.37%
Dividend- P/FCF- EPS past 5Y-54.80% ROI-60.90% 52W High-63.23% Beta-0.81
Dividend %- Quick Ratio1.90 Sales past 5Y0.30% Gross Margin23.90% 52W Low319.51% ATR0.71
Employees39 Current Ratio3.00 Sales Q/Q-7.70% Oper. Margin-50.90% RSI (14)63.35 Volatility7.90% 10.89%
OptionableNo Debt/Eq0.00 EPS Q/Q-20.50% Profit Margin-51.40% Rel Volume0.41 Prev Close8.69
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume865.56K Price8.60
Recom- SMA2022.27% SMA5025.34% SMA20084.07% Volume301,553 Change-1.04%
Jan-04-18Initiated B. Riley FBR, Inc. Buy $7.50
Jun-29-20 09:39PM  
Jun-16-20 08:19AM  
Jun-06-20 08:01AM  
Jun-01-20 07:38AM  
May-27-20 07:20AM  
May-14-20 06:40AM  
May-07-20 10:27AM  
Apr-15-20 08:30AM  
Apr-03-20 08:28PM  
Apr-02-20 07:38AM  
Apr-01-20 11:43AM  
Mar-30-20 06:22AM  
Mar-19-20 07:37AM  
Mar-18-20 07:36AM  
Mar-17-20 08:16PM  
Feb-26-20 04:41PM  
Feb-13-20 05:15AM  
Jan-15-20 08:19AM  
Jan-09-20 05:45AM  
Jan-07-20 08:19AM  
Dec-04-19 07:00AM  
Oct-29-19 06:43AM  
Oct-16-19 08:19AM  
Sep-29-19 09:15AM  
Sep-19-19 10:15AM  
Aug-30-19 10:31AM  
Aug-21-19 08:19AM  
Jul-25-19 11:33AM  
Jun-19-19 02:28PM  
Jun-05-19 08:19AM  
Apr-25-19 10:06AM  
Apr-22-19 11:00AM  
Apr-16-19 09:18AM  
Apr-08-19 08:19AM  
Mar-12-19 08:45AM  
Feb-21-19 02:49PM  
Feb-05-19 08:19AM  
Jan-22-19 02:42PM  
Jan-21-19 11:00AM  
Jan-15-19 08:19AM  
Nov-28-18 08:19AM  
Nov-16-18 08:55AM  
Nov-07-18 09:42AM  
Oct-22-18 01:15PM  
Oct-16-18 08:30AM  
Sep-26-18 12:00PM  
Sep-07-18 10:00AM  
Aug-30-18 08:19AM  
Aug-02-18 08:19AM  
Jun-25-18 08:19AM  
May-31-18 08:26PM  
May-10-18 05:55PM  
Apr-19-18 09:45AM  
Apr-17-18 03:01PM  
Mar-08-18 08:19AM  
Mar-01-18 06:11PM  
Jan-23-18 09:45AM  
Jan-19-18 10:54AM  
Jan-16-18 09:18AM  
Jan-10-18 08:19AM  
Jan-09-18 08:43AM  
Jan-08-18 08:19AM  
Jan-01-18 06:55PM  
Dec-25-17 11:35AM  
Dec-07-17 04:23PM  
Nov-20-17 08:19AM  
Nov-13-17 05:25PM  
Nov-07-17 08:19AM  
Oct-20-17 11:00AM  
Oct-17-17 08:37AM  
Sep-20-17 09:30AM  
Sep-12-17 08:19AM  
Sep-06-17 01:00PM  
Aug-31-17 10:34AM  
Aug-30-17 01:03PM  
Aug-16-17 08:19AM  
May-23-17 07:29AM  
Apr-18-17 02:00PM  
Apr-17-17 08:19AM  
Mar-09-17 08:19AM  
Jan-26-17 10:30AM  
Jan-21-17 01:04PM  
Jan-18-17 11:24AM  
Jan-17-17 04:18PM  
Nov-30-16 09:00AM  
Oct-20-16 09:00AM  
Oct-19-16 09:22AM  
Oct-18-16 07:57AM  
Oct-17-16 04:18PM  
Oct-04-16 07:57AM  
Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point of care and clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sirgo Mark ADirectorApr 21Sale8.115,00040,5328,700Apr 21 04:57 PM
Sirgo Mark ADirectorApr 17Sale8.075,00040,34613,700Apr 21 04:57 PM